Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 35Neoplasm Metastasis 7Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Thyroid Neoplasms 4Thyroid Cancer, Papillary 3Sarcoma 3Pancreatic Neoplasms 3Neoplasms by Site 3Melanoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Diseases 2Thoracic Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Lung Diseases 2Esophageal Neoplasms 2Endometrial Neoplasms 2Endocrine System Diseases 2

Interventions

trastuzumab deruxtecan 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × HER2-Positive Primary Breast Cancer × Breast × Clear all
NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡